Autolus Therapeutics to Participate in Upcoming Investor Conferences

Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces that the Company will present and host meetings at two upcoming investor conferences.

William Blair’s 46th Annual Growth Stock Conference Date and time: June 2, 2026; 1:20pm CDT / 7:20pm BST Location: Chicago, IL Presenter: Chief Executive Officer Dr. Christian Itin

Jefferies Global Healthcare Conference Date and time: June 3, 2026; 10:30am EDT / 3:30pm BST Location: New York, NY Presenter: Chief Executive Officer Dr. Christian Itin

Webcasts of the presentations will be available on the “Events” page in the “Investor Relations & Media” section of the Company’s website at https://www.autolus.com/investor-relations-media/events/ . A replay of the webcasts will be archived on the Company’s website for 90 days following the presentations.

About Autolus Therapeutics plc Autolus Therapeutics plc (Nasdaq: AUTL) is a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies and candidates for the treatment of cancer and autoimmune disease. Using a broad suite of proprietary and modular T cell programming technologies, Autolus is engineering precisely targeted and controlled T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and eliminate these cells. Autolus has a marketed therapy, AUCATZYL ® , and a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. For more information, please visit www.autolus.com .

Contact:

Amanda Cray +1 617-967-0207 [email protected]